

HepCaRe

Hepatitis **C** Antiviral therapy failure **R**egistry

Are you working with HCV infected patients and would like to collaborate in a European multi-center study to get further insights in therapy failure, please contribute by submitting data!

Background

The efficacy of HCV regimens with DAA medication is influenced by the presence of certain resistant associated variants (RAVs). To analyze the occurrence of RAVs associated with DAA treatment failure in daily practice across Europe and to analyze the influences of different genotypes varied by patient characteristics or virological characteristics on treatment failure, larger datasets are required. With HepCare we want to establish a European registry for clinical cases of DAA treatment failure.

Why collaborate?

- **Participation in the ESAR HCV workgroup**
- **Submission does not change ownership data**
- **Contribute into better patient care**
- **Joint publications**

Data entry will take less than 5 minutes

Inclusion criteria:

- > 18 years old
- HCV infection
- Failure/relapse on DAA regime



Joop Arends



Charles Boucher



Carlo Federico Perno



Stephanie Popping



Annemarie Wensing



Carole Devaux